Issels Integrative Immuno-Oncology March 22, 2018  

Focus on Cancer Prognosis Through the Host Tissue

Dear Friend,

Thanks to innovations in testing methods and proactive awareness campaigns, doctors are able to diagnose cancer earlier than ever, increasing the chances of successful cancer immunotherapy. The second part of the equation, predicting the degree of malignancy, is a puzzle that remains to be solved.

When Is a Patient Truly Free of Cancer?

After treatment, a patient who shows no signs of cancer cells is classified as "no evidence of disease." While the patient may display no visible tumors, doctors have no way of knowing if the cells have metastasized to other areas of the body where they may later resurface.

Chemotherapy and other treatments are often prescribed to decrease the chance of metastasis. Doctors tend to err on the side of caution, assuming that all patients are vulnerable, so many endure grueling rounds of treatment that end up being unnecessary.

"Focus on the Soil, Not the Seed"

For the most part, researchers have concentrated on unraveling the mysteries of cancer cells themselves to understand how they grow and spread. In keeping with that approach, scientists believed that metastasis was caused by cells spreading outward from their original location.

Based on that theory, all cancer patients would be expected to have metastasis. Many researchers are now shifting to a view that the spread of cancer cells is caused by a pathological relationship between the diseased cells and the host environment.

State-of-the-Art Cancer Immunotherapy from Issels®

Cancer immunotherapy at Issels® is directed at the cancer cells along with the underlying causes for the development of tumors. Contact us to learn more about how Issels® has helped patients achieve long-term remission.

Focus on Cancer Prognosis Through the Host Tissue

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »


Presence of the Protein Csn6 in Bowel Tumors Linked To a Poorer Bowel Cancer Prognosis

Samples from patients suffering from bowel cancer were examined for a protein molecule called CSN6. This protein molecule is a regulator for multiple pathways.

Researchers looked at tissue samples from the actual tumor. In cases where the CSN6 molecule was found to be present, the colorectal cancer prognosis was determined to have a much shorter recurrence-free survival rate.

In other words, where this protein molecule was found, those patients were more likely to have a recurrence of the colorectal cancer than in patients whose tumor samples did not contain the protein molecule.

Get the Full Story!

Three Tips to Understanding Your Cancer's Prognosis

Though it may mystify the patient to some extent, a doctor's cancer prognosis is thoroughly grounded in his own and his peer's medical experience. The doctor will look at such things as the type and location of the cancer, its metastatic stage – that is, how much it has actually spread – and the cancer's grade – how abnormal it looks and how likely it is to spread even more.

While your prognosis is your doctor's "best guess" as to the likely course and outcome of your disease, it is by no means 100% certain. Remaining positive throughout the process is always the best medicine. As you can see, a prognosis is as much art as it is science and the best doctors combine both when making a prognosis.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!
Interested?

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:


Google +

Contact Info:

Phone: 888-447-7357

Email: info@issels.com



Treatments | Testimonials | Contact Us